 | • レポートコード：QFJ1-5881 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、神経代謝障害の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ゴーシェ病、ファブリー病、ポンペ病、ムコ多糖症VI型、その他）、用途別市場規模（経口、非経口）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・神経代謝障害の市場動向 ・企業の競争状況、市場シェア ・神経代謝障害の種類別市場規模と予測2016-2027（ゴーシェ病、ファブリー病、ポンペ病、ムコ多糖症VI型、その他） ・神経代謝障害の用途別市場規模と予測2016-2027（経口、非経口） ・神経代謝障害の北米市場規模2016-2027（アメリカ、カナダ） ・神経代謝障害の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・神経代謝障害のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・神経代謝障害の中南米市場規模2016-2027（メキシコ、ブラジル） ・神経代謝障害の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Amicus Therapeutics、ISU Abxis、JCR Pharmaceuticals、Biosidus、Greenovation Biotech、UAB Proforma、Dong-A Socio Group、ExSAR Corporation、Lixte Biotechnology、Neuraltus Pharmaceuticals、Protalix、Pharming Group、Protalix BioTherapeutics、Amicus、Biomarin、Genzyme、Shire、Greencross） ・結論 |
Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.
Market Analysis and Insights: Global Neurometabolic Disorders Market
The global Neurometabolic Disorders market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurometabolic Disorders market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurometabolic Disorders market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurometabolic Disorders market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurometabolic Disorders market.
Global Neurometabolic Disorders Scope and Market Size
Neurometabolic Disorders market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurometabolic Disorders market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Gaucher’s Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis VI
Other
Segment by Application
Oral
Parenteral
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurometabolic Disorders Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Gaucher’s Disease
1.2.3 Fabry Disease
1.2.4 Pompe Disease
1.2.5 Mucopolysaccharidosis VI
1.2.6 Other
1.3 Market by Application
1.3.1 Global Neurometabolic Disorders Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oral
1.3.3 Parenteral
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurometabolic Disorders Market Perspective (2016-2027)
2.2 Neurometabolic Disorders Growth Trends by Regions
2.2.1 Neurometabolic Disorders Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurometabolic Disorders Historic Market Share by Regions (2016-2021)
2.2.3 Neurometabolic Disorders Forecasted Market Size by Regions (2022-2027)
2.3 Neurometabolic Disorders Industry Dynamic
2.3.1 Neurometabolic Disorders Market Trends
2.3.2 Neurometabolic Disorders Market Drivers
2.3.3 Neurometabolic Disorders Market Challenges
2.3.4 Neurometabolic Disorders Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurometabolic Disorders Players by Revenue
3.1.1 Global Top Neurometabolic Disorders Players by Revenue (2016-2021)
3.1.2 Global Neurometabolic Disorders Revenue Market Share by Players (2016-2021)
3.2 Global Neurometabolic Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurometabolic Disorders Revenue
3.4 Global Neurometabolic Disorders Market Concentration Ratio
3.4.1 Global Neurometabolic Disorders Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurometabolic Disorders Revenue in 2020
3.5 Neurometabolic Disorders Key Players Head office and Area Served
3.6 Key Players Neurometabolic Disorders Product Solution and Service
3.7 Date of Enter into Neurometabolic Disorders Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurometabolic Disorders Breakdown Data by Type
4.1 Global Neurometabolic Disorders Historic Market Size by Type (2016-2021)
4.2 Global Neurometabolic Disorders Forecasted Market Size by Type (2022-2027)
5 Neurometabolic Disorders Breakdown Data by Application
5.1 Global Neurometabolic Disorders Historic Market Size by Application (2016-2021)
5.2 Global Neurometabolic Disorders Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Neurometabolic Disorders Market Size (2016-2027)
6.2 North America Neurometabolic Disorders Market Size by Type
6.2.1 North America Neurometabolic Disorders Market Size by Type (2016-2021)
6.2.2 North America Neurometabolic Disorders Market Size by Type (2022-2027)
6.2.3 North America Neurometabolic Disorders Market Size by Type (2016-2027)
6.3 North America Neurometabolic Disorders Market Size by Application
6.3.1 North America Neurometabolic Disorders Market Size by Application (2016-2021)
6.3.2 North America Neurometabolic Disorders Market Size by Application (2022-2027)
6.3.3 North America Neurometabolic Disorders Market Size by Application (2016-2027)
6.4 North America Neurometabolic Disorders Market Size by Country
6.4.1 North America Neurometabolic Disorders Market Size by Country (2016-2021)
6.4.2 North America Neurometabolic Disorders Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Neurometabolic Disorders Market Size (2016-2027)
7.2 Europe Neurometabolic Disorders Market Size by Type
7.2.1 Europe Neurometabolic Disorders Market Size by Type (2016-2021)
7.2.2 Europe Neurometabolic Disorders Market Size by Type (2022-2027)
7.2.3 Europe Neurometabolic Disorders Market Size by Type (2016-2027)
7.3 Europe Neurometabolic Disorders Market Size by Application
7.3.1 Europe Neurometabolic Disorders Market Size by Application (2016-2021)
7.3.2 Europe Neurometabolic Disorders Market Size by Application (2022-2027)
7.3.3 Europe Neurometabolic Disorders Market Size by Application (2016-2027)
7.4 Europe Neurometabolic Disorders Market Size by Country
7.4.1 Europe Neurometabolic Disorders Market Size by Country (2016-2021)
7.4.2 Europe Neurometabolic Disorders Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Neurometabolic Disorders Market Size (2016-2027)
8.2 Asia-Pacific Neurometabolic Disorders Market Size by Type
8.2.1 Asia-Pacific Neurometabolic Disorders Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurometabolic Disorders Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurometabolic Disorders Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurometabolic Disorders Market Size by Application
8.3.1 Asia-Pacific Neurometabolic Disorders Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurometabolic Disorders Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurometabolic Disorders Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurometabolic Disorders Market Size by Region
8.4.1 Asia-Pacific Neurometabolic Disorders Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurometabolic Disorders Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neurometabolic Disorders Market Size (2016-2027)
9.2 Latin America Neurometabolic Disorders Market Size by Type
9.2.1 Latin America Neurometabolic Disorders Market Size by Type (2016-2021)
9.2.2 Latin America Neurometabolic Disorders Market Size by Type (2022-2027)
9.2.3 Latin America Neurometabolic Disorders Market Size by Type (2016-2027)
9.3 Latin America Neurometabolic Disorders Market Size by Application
9.3.1 Latin America Neurometabolic Disorders Market Size by Application (2016-2021)
9.3.2 Latin America Neurometabolic Disorders Market Size by Application (2022-2027)
9.3.3 Latin America Neurometabolic Disorders Market Size by Application (2016-2027)
9.4 Latin America Neurometabolic Disorders Market Size by Country
9.4.1 Latin America Neurometabolic Disorders Market Size by Country (2016-2021)
9.4.2 Latin America Neurometabolic Disorders Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurometabolic Disorders Market Size (2016-2027)
10.2 Middle East & Africa Neurometabolic Disorders Market Size by Type
10.2.1 Middle East & Africa Neurometabolic Disorders Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurometabolic Disorders Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurometabolic Disorders Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurometabolic Disorders Market Size by Application
10.3.1 Middle East & Africa Neurometabolic Disorders Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurometabolic Disorders Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurometabolic Disorders Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurometabolic Disorders Market Size by Country
10.4.1 Middle East & Africa Neurometabolic Disorders Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurometabolic Disorders Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Amicus Therapeutics
11.1.1 Amicus Therapeutics Company Details
11.1.2 Amicus Therapeutics Business Overview
11.1.3 Amicus Therapeutics Neurometabolic Disorders Introduction
11.1.4 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2016-2021)
11.1.5 Amicus Therapeutics Recent Development
11.2 ISU Abxis
11.2.1 ISU Abxis Company Details
11.2.2 ISU Abxis Business Overview
11.2.3 ISU Abxis Neurometabolic Disorders Introduction
11.2.4 ISU Abxis Revenue in Neurometabolic Disorders Business (2016-2021)
11.2.5 ISU Abxis Recent Development
11.3 JCR Pharmaceuticals
11.3.1 JCR Pharmaceuticals Company Details
11.3.2 JCR Pharmaceuticals Business Overview
11.3.3 JCR Pharmaceuticals Neurometabolic Disorders Introduction
11.3.4 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2016-2021)
11.3.5 JCR Pharmaceuticals Recent Development
11.4 Biosidus
11.4.1 Biosidus Company Details
11.4.2 Biosidus Business Overview
11.4.3 Biosidus Neurometabolic Disorders Introduction
11.4.4 Biosidus Revenue in Neurometabolic Disorders Business (2016-2021)
11.4.5 Biosidus Recent Development
11.5 Greenovation Biotech
11.5.1 Greenovation Biotech Company Details
11.5.2 Greenovation Biotech Business Overview
11.5.3 Greenovation Biotech Neurometabolic Disorders Introduction
11.5.4 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2016-2021)
11.5.5 Greenovation Biotech Recent Development
11.6 UAB Proforma
11.6.1 UAB Proforma Company Details
11.6.2 UAB Proforma Business Overview
11.6.3 UAB Proforma Neurometabolic Disorders Introduction
11.6.4 UAB Proforma Revenue in Neurometabolic Disorders Business (2016-2021)
11.6.5 UAB Proforma Recent Development
11.7 Dong-A Socio Group
11.7.1 Dong-A Socio Group Company Details
11.7.2 Dong-A Socio Group Business Overview
11.7.3 Dong-A Socio Group Neurometabolic Disorders Introduction
11.7.4 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2016-2021)
11.7.5 Dong-A Socio Group Recent Development
11.8 ExSAR Corporation
11.8.1 ExSAR Corporation Company Details
11.8.2 ExSAR Corporation Business Overview
11.8.3 ExSAR Corporation Neurometabolic Disorders Introduction
11.8.4 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2016-2021)
11.8.5 ExSAR Corporation Recent Development
11.9 Lixte Biotechnology
11.9.1 Lixte Biotechnology Company Details
11.9.2 Lixte Biotechnology Business Overview
11.9.3 Lixte Biotechnology Neurometabolic Disorders Introduction
11.9.4 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2016-2021)
11.9.5 Lixte Biotechnology Recent Development
11.10 Neuraltus Pharmaceuticals
11.10.1 Neuraltus Pharmaceuticals Company Details
11.10.2 Neuraltus Pharmaceuticals Business Overview
11.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Introduction
11.10.4 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2016-2021)
11.10.5 Neuraltus Pharmaceuticals Recent Development
11.11 Protalix
11.11.1 Protalix Company Details
11.11.2 Protalix Business Overview
11.11.3 Protalix Neurometabolic Disorders Introduction
11.11.4 Protalix Revenue in Neurometabolic Disorders Business (2016-2021)
11.11.5 Protalix Recent Development
11.12 Pharming Group
11.12.1 Pharming Group Company Details
11.12.2 Pharming Group Business Overview
11.12.3 Pharming Group Neurometabolic Disorders Introduction
11.12.4 Pharming Group Revenue in Neurometabolic Disorders Business (2016-2021)
11.12.5 Pharming Group Recent Development
11.13 Protalix BioTherapeutics
11.13.1 Protalix BioTherapeutics Company Details
11.13.2 Protalix BioTherapeutics Business Overview
11.13.3 Protalix BioTherapeutics Neurometabolic Disorders Introduction
11.13.4 Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2016-2021)
11.13.5 Protalix BioTherapeutics Recent Development
11.14 Amicus
11.14.1 Amicus Company Details
11.14.2 Amicus Business Overview
11.14.3 Amicus Neurometabolic Disorders Introduction
11.14.4 Amicus Revenue in Neurometabolic Disorders Business (2016-2021)
11.14.5 Amicus Recent Development
11.15 Biomarin
11.15.1 Biomarin Company Details
11.15.2 Biomarin Business Overview
11.15.3 Biomarin Neurometabolic Disorders Introduction
11.15.4 Biomarin Revenue in Neurometabolic Disorders Business (2016-2021)
11.15.5 Biomarin Recent Development
11.16 Genzyme
11.16.1 Genzyme Company Details
11.16.2 Genzyme Business Overview
11.16.3 Genzyme Neurometabolic Disorders Introduction
11.16.4 Genzyme Revenue in Neurometabolic Disorders Business (2016-2021)
11.16.5 Genzyme Recent Development
11.17 Shire
11.17.1 Shire Company Details
11.17.2 Shire Business Overview
11.17.3 Shire Neurometabolic Disorders Introduction
11.17.4 Shire Revenue in Neurometabolic Disorders Business (2016-2021)
11.17.5 Shire Recent Development
11.18 Greencross
11.18.1 Greencross Company Details
11.18.2 Greencross Business Overview
11.18.3 Greencross Neurometabolic Disorders Introduction
11.18.4 Greencross Revenue in Neurometabolic Disorders Business (2016-2021)
11.18.5 Greencross Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Neurometabolic Disorders Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Gaucher’s Disease
Table 3. Key Players of Fabry Disease
Table 4. Key Players of Pompe Disease
Table 5. Key Players of Mucopolysaccharidosis VI
Table 6. Key Players of Other
Table 7. Global Neurometabolic Disorders Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Neurometabolic Disorders Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Neurometabolic Disorders Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Neurometabolic Disorders Market Share by Regions (2016-2021)
Table 11. Global Neurometabolic Disorders Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Neurometabolic Disorders Market Share by Regions (2022-2027)
Table 13. Neurometabolic Disorders Market Trends
Table 14. Neurometabolic Disorders Market Drivers
Table 15. Neurometabolic Disorders Market Challenges
Table 16. Neurometabolic Disorders Market Restraints
Table 17. Global Neurometabolic Disorders Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Neurometabolic Disorders Market Share by Players (2016-2021)
Table 19. Global Top Neurometabolic Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurometabolic Disorders as of 2020)
Table 20. Ranking of Global Top Neurometabolic Disorders Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Neurometabolic Disorders Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurometabolic Disorders Product Solution and Service
Table 24. Date of Enter into Neurometabolic Disorders Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Neurometabolic Disorders Revenue Market Share by Type (2016-2021)
Table 28. Global Neurometabolic Disorders Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Neurometabolic Disorders Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Neurometabolic Disorders Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Neurometabolic Disorders Revenue Market Share by Application (2016-2021)
Table 32. Global Neurometabolic Disorders Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Neurometabolic Disorders Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Neurometabolic Disorders Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Neurometabolic Disorders Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Neurometabolic Disorders Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Neurometabolic Disorders Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Neurometabolic Disorders Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Neurometabolic Disorders Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Neurometabolic Disorders Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Neurometabolic Disorders Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Neurometabolic Disorders Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Neurometabolic Disorders Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neurometabolic Disorders Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neurometabolic Disorders Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Neurometabolic Disorders Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Neurometabolic Disorders Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Neurometabolic Disorders Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Neurometabolic Disorders Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Neurometabolic Disorders Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Neurometabolic Disorders Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Neurometabolic Disorders Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Neurometabolic Disorders Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neurometabolic Disorders Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neurometabolic Disorders Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Neurometabolic Disorders Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Neurometabolic Disorders Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Neurometabolic Disorders Market Size by Country (2022-2027) & (US$ Million)
Table 64. Amicus Therapeutics Company Details
Table 65. Amicus Therapeutics Business Overview
Table 66. Amicus Therapeutics Neurometabolic Disorders Product
Table 67. Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 68. Amicus Therapeutics Recent Development
Table 69. ISU Abxis Company Details
Table 70. ISU Abxis Business Overview
Table 71. ISU Abxis Neurometabolic Disorders Product
Table 72. ISU Abxis Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 73. ISU Abxis Recent Development
Table 74. JCR Pharmaceuticals Company Details
Table 75. JCR Pharmaceuticals Business Overview
Table 76. JCR Pharmaceuticals Neurometabolic Disorders Product
Table 77. JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 78. JCR Pharmaceuticals Recent Development
Table 79. Biosidus Company Details
Table 80. Biosidus Business Overview
Table 81. Biosidus Neurometabolic Disorders Product
Table 82. Biosidus Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 83. Biosidus Recent Development
Table 84. Greenovation Biotech Company Details
Table 85. Greenovation Biotech Business Overview
Table 86. Greenovation Biotech Neurometabolic Disorders Product
Table 87. Greenovation Biotech Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 88. Greenovation Biotech Recent Development
Table 89. UAB Proforma Company Details
Table 90. UAB Proforma Business Overview
Table 91. UAB Proforma Neurometabolic Disorders Product
Table 92. UAB Proforma Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 93. UAB Proforma Recent Development
Table 94. Dong-A Socio Group Company Details
Table 95. Dong-A Socio Group Business Overview
Table 96. Dong-A Socio Group Neurometabolic Disorders Product
Table 97. Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 98. Dong-A Socio Group Recent Development
Table 99. ExSAR Corporation Company Details
Table 100. ExSAR Corporation Business Overview
Table 101. ExSAR Corporation Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 102. ExSAR Corporation Recent Development
Table 103. Lixte Biotechnology Company Details
Table 104. Lixte Biotechnology Business Overview
Table 105. Lixte Biotechnology Neurometabolic Disorders Product
Table 106. Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 107. Lixte Biotechnology Recent Development
Table 108. Neuraltus Pharmaceuticals Company Details
Table 109. Neuraltus Pharmaceuticals Business Overview
Table 110. Neuraltus Pharmaceuticals Neurometabolic Disorders Product
Table 111. Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 112. Neuraltus Pharmaceuticals Recent Development
Table 113. Protalix Company Details
Table 114. Protalix Business Overview
Table 115. Protalix Neurometabolic Disorders Product
Table 116. Protalix Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 117. Protalix Recent Development
Table 118. Pharming Group Company Details
Table 119. Pharming Group Business Overview
Table 120. Pharming Group Neurometabolic Disorders Product
Table 121. Pharming Group Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 122. Pharming Group Recent Development
Table 123. Protalix BioTherapeutics Company Details
Table 124. Protalix BioTherapeutics Business Overview
Table 125. Protalix BioTherapeutics Neurometabolic Disorders Product
Table 126. Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 127. Protalix BioTherapeutics Recent Development
Table 128. Amicus Company Details
Table 129. Amicus Business Overview
Table 130. Amicus Neurometabolic Disorders Product
Table 131. Amicus Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 132. Amicus Recent Development
Table 133. Biomarin Company Details
Table 134. Biomarin Business Overview
Table 135. Biomarin Neurometabolic Disorders Product
Table 136. Biomarin Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 137. Biomarin Recent Development
Table 138. Genzyme Company Details
Table 139. Genzyme Business Overview
Table 140. Genzyme Neurometabolic Disorders Product
Table 141. Genzyme Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 142. Genzyme Recent Development
Table 143. Shire Company Details
Table 144. Shire Business Overview
Table 145. Shire Neurometabolic Disorders Product
Table 146. Shire Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 147. Shire Recent Development
Table 148. Greencross Company Details
Table 149. Greencross Business Overview
Table 150. Greencross Neurometabolic Disorders Product
Table 151. Greencross Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
Table 152. Greencross Recent Development
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurometabolic Disorders Market Share by Type: 2020 VS 2027
Figure 2. Gaucher’s Disease Features
Figure 3. Fabry Disease Features
Figure 4. Pompe Disease Features
Figure 5. Mucopolysaccharidosis VI Features
Figure 6. Other Features
Figure 7. Global Neurometabolic Disorders Market Share by Application: 2020 VS 2027
Figure 8. Oral Case Studies
Figure 9. Parenteral Case Studies
Figure 10. Neurometabolic Disorders Report Years Considered
Figure 11. Global Neurometabolic Disorders Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Neurometabolic Disorders Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Neurometabolic Disorders Market Share by Regions: 2020 VS 2027
Figure 14. Global Neurometabolic Disorders Market Share by Regions (2022-2027)
Figure 15. Global Neurometabolic Disorders Market Share by Players in 2020
Figure 16. Global Top Neurometabolic Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurometabolic Disorders as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Neurometabolic Disorders Revenue in 2020
Figure 18. Global Neurometabolic Disorders Revenue Market Share by Type (2016-2021)
Figure 19. Global Neurometabolic Disorders Revenue Market Share by Type (2022-2027)
Figure 20. North America Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Neurometabolic Disorders Market Share by Type (2016-2027)
Figure 22. North America Neurometabolic Disorders Market Share by Application (2016-2027)
Figure 23. North America Neurometabolic Disorders Market Share by Country (2016-2027)
Figure 24. United States Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neurometabolic Disorders Market Share by Type (2016-2027)
Figure 28. Europe Neurometabolic Disorders Market Share by Application (2016-2027)
Figure 29. Europe Neurometabolic Disorders Market Share by Country (2016-2027)
Figure 30. Germany Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neurometabolic Disorders Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Neurometabolic Disorders Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Neurometabolic Disorders Market Share by Region (2016-2027)
Figure 40. China Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neurometabolic Disorders Market Share by Type (2016-2027)
Figure 48. Latin America Neurometabolic Disorders Market Share by Application (2016-2027)
Figure 49. Latin America Neurometabolic Disorders Market Share by Country (2016-2027)
Figure 50. Mexico Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neurometabolic Disorders Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Neurometabolic Disorders Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Neurometabolic Disorders Market Share by Country (2016-2027)
Figure 56. Turkey Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Amicus Therapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 60. ISU Abxis Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 61. JCR Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 62. Biosidus Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 63. Greenovation Biotech Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 64. UAB Proforma Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 65. Dong-A Socio Group Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 66. ExSAR Corporation Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 67. Lixte Biotechnology Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 68. Neuraltus Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 69. Protalix Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 70. Pharming Group Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 71. Protalix BioTherapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 72. Amicus Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 73. Biomarin Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 74. Genzyme Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 75. Shire Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 76. Greencross Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
世界のゴーシェ病（GD）治療薬市場規模・現状・予測（2021年-2027年） Gaucher disease is an inherited disorder that affects many of the body's organs and tissues. The signs and symptoms of this condition vary widely among affected individuals. Market Analysis and Insights: Global Gaucher Disease (GD) Drugs Market The global Gaucher Disease (GD) Drugs market size is pr…- 世界のファブリー病治療市場規模・現状・予測（2021年-2027年） Fabry disease is a rare X-linked lysosomal storage disorder with a deficiency of alpha galactosidase enzyme resulting in progressive organ dysfunction. This disease is caused by abnormal buildup of a specific fatty matter called globotriaosylceramide in multiple tissues of the body including eyes, s…
- 世界のゴーシェ病＆ポンペ病酵素補充療法（ERT）市場規模・現状・予測（2021年-2027年） A type of resistance measuring device which measure the grounding resistance of various devices and the conductor resistance of low resistance. Market Analysis and Insights: Global Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market The global Gaucher and Pompe Diseases Enzyme Replace…
- 世界のゴーシェ病＆ポンペ病酵素補充療法市場規模・現状・予測（2021年-2027年） Enzyme replacement therapy (ERT) involves intravenous (IV) infusions to correct the underlying enzyme deficiency that causes symptoms of Gaucher disease Market Analysis and Insights: Global Gaucher and Pompe Diseases Enzyme Replacement Therapy Market The global Gaucher and Pompe Diseases Enzyme Repl…
- 世界のフォン・ヴィレブランド病治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Von Willebrand Disease Treatment Market The global Von Willebrand Disease Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data…